Pharma teams can now assess biomarker coverage across datma’s federated network with no cost, contracts, or IT support required.
datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows pharmaceutical teams to evaluate real-world biomarker coverage across datma’s federated network of participating data contributors before entering into a formal data partnership. This tool is designed to help teams answer a critical question early in the data sourcing process: Does this dataset contain the patient populations we need?
The Federated Biomarker Explorer provides aggregate, cohort-level visibility into biomarker presence across the datma federated network. Teams can filter by a range of clinical and demographic attributes to assess feasibility. No data integration, procurement involvement, or internal IT support is required, making the application immediately accessible for teams looking to validate coverage before taking the next step.
If alignment is found between datma’s network and a team’s target population, users can choose to link their own data to conduct a formal overlap analysis. This is done securely, without centralizing or transferring sensitive patient-level data.
“Pharma teams often find themselves committing time and resources into exploratory conversations or technical scoping before they can even determine whether a dataset is relevant,” said Robin Edison, the VP of Product at datma. “This tool lets users quickly answer the question: is this data feasible for my use case?”
The launch supports datma’s broader goal of reducing friction in real-world data collaboration by making the evaluation process faster and lower risk. Instead of requiring lengthy intake processes just to understand what’s in a dataset, the Federated Biomarker Explorer offers visibility and usability from the start.
“We believe access should begin with clarity,” said Noah Nasser, CEO of datma. “Teams shouldn’t need to invest time, budget, or legal resources just to learn whether a dataset can support their goals.”
For users who identify a fit and choose to move forward, datma.FED enables federated analysis across internal and external datasets without moving or centralizing sensitive information. This allows teams to augment their existing data with targeted real-world cohorts, helping address specific research or market access questions that fall outside the scope of their current assets. By filling gaps rather than replacing what’s already in place, datma offers a faster, more efficient path to insights.
The Federated Biomarker Explorer is now live and available to pharmaceutical and life sciences teams. To learn more or request access, visit datma.com/trial
